Bank of New York Mellon Corp Sells 3,777 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN)

Bank of New York Mellon Corp reduced its position in Design Therapeutics, Inc. (NASDAQ:DSGN) by 3.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 95,348 shares of the company’s stock after selling 3,777 shares during the quarter. Bank of New York Mellon Corp owned about 0.17% of Design Therapeutics worth $588,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Frazier Life Sciences Management L.P. increased its stake in Design Therapeutics by 58.3% in the third quarter. Frazier Life Sciences Management L.P. now owns 1,892,547 shares of the company’s stock valued at $10,182,000 after acquiring an additional 697,368 shares during the last quarter. Baker BROS. Advisors LP increased its stake in shares of Design Therapeutics by 2.9% in the 3rd quarter. Baker BROS. Advisors LP now owns 1,743,725 shares of the company’s stock valued at $9,381,000 after purchasing an additional 48,431 shares during the last quarter. Point72 Asset Management L.P. increased its stake in shares of Design Therapeutics by 61.6% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,600,740 shares of the company’s stock valued at $8,612,000 after purchasing an additional 609,939 shares during the last quarter. FMR LLC raised its holdings in shares of Design Therapeutics by 922.8% during the 3rd quarter. FMR LLC now owns 828,665 shares of the company’s stock worth $4,458,000 after buying an additional 747,649 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Design Therapeutics by 7.1% during the 3rd quarter. Geode Capital Management LLC now owns 758,550 shares of the company’s stock worth $4,081,000 after buying an additional 50,579 shares during the last quarter. 56.64% of the stock is currently owned by institutional investors and hedge funds.

Design Therapeutics Stock Up 1.0 %

Design Therapeutics stock opened at $4.19 on Friday. The stock has a market cap of $237.84 million, a PE ratio of -4.93 and a beta of 1.77. Design Therapeutics, Inc. has a 12-month low of $3.15 and a 12-month high of $7.77. The business’s 50-day moving average price is $4.71 and its two-hundred day moving average price is $5.34.

Design Therapeutics (NASDAQ:DSGN) last announced its quarterly earnings results on Monday, March 10th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.04. As a group, analysts expect that Design Therapeutics, Inc. will post -0.91 earnings per share for the current year.

Design Therapeutics Company Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.